Conjugated estrogens
- Generic Name
- Conjugated estrogens
- Brand Names
- Congest, Duavee, Duavive, Premarin, Premphase 28 Day, Prempro 0.625/2.5 28 Day
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 12126-59-9
- Unique Ingredient Identifier
- IU5QR144QX
- Background
The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.
...
- Indication
The conjugated estrogens are indicated for several different conditions including:
- Associated Conditions
- Abnormal Uterine Bleeding, Atrophic Vaginitis, Atrophy of vulva, Kraurosis Vulvae, Menopause, Metastatic Breast Cancer, Moderate to Severe Vasomotor Symptoms, Osteoporosis, Androgen-dependent tumor Advanced Prostate Carcinoma, Hypoestrogenism, Moderate Dyspareunia, Moderate Vulvar and Vaginal Atrophy, Severe Dyspareunia, Severe Vulvar and Vaginal Atrophy
- Associated Therapies
- Estrogen Replacement Therapy, Palliative Treatment
AFTER: Altering Fat Through Estrogen and Raloxifene
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2009-12-02
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 108
- Registration Number
- NCT00149604
- Locations
- ๐บ๐ธ
University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT00134654
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2009-05-12
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Registration Number
- NCT00079248
- Locations
- ๐ฌ๐ง
Institute of Cancer Research - UK, Sutton, England, United Kingdom
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
- Conditions
- First Posted Date
- 2003-09-17
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00026286
- Locations
- ๐บ๐ธ
CCOP - Carle Cancer Center, Urbana, Illinois, United States
๐บ๐ธCCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
๐บ๐ธCCOP - Northern New Jersey, Hackensack, New Jersey, United States
Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 2108
- Registration Number
- NCT00002976
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
๐บ๐ธVeterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Target Recruit Count
- 150
- Registration Number
- NCT00004650
Postmenopausal Estrogen/Progestin Interventions (PEPI)
Soy Estrogen Alternative Study (SEA)
Women's Angiographic Vitamin and Estrogen Trial (WAVE)
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.